Unnamed corporates have provided capital for Panlin’s $148m fund that will focus on healthcare, digital transformation and smart hardware.

Tal Heppenstall will stand down as president of UPMC Enterprises to be replaced by Jeanne Cunicelli, promoted from executive vice-president.

K Wah Group’s subsidiary has taken part in the tumour therapy and drug developer’s $29.3m round, which came a year after its $28m series B round.

Global University Venturing: Covid-19 remains a threat but universities are at the forefront of fighting back

The Washington State University neurological drug developer has gone public after issuing 12 million shares priced at $17 each.

The testing services provider hiked its overall funding to more than $68m in a round backed by Alibaba Hong Kong Entrepreneurs Fund.

Novartis-backed Inflazome, which advances University of Queensland and Trinity College Dublin research to develop treatments for inflammation, has been bought by Roche for $448m.

Inflazome, which advances University of Queensland and Trinity College Dublin research to develop treatments for inflammation, has been bought by Roche for $448m.

Compass Pathways has raised more than $127m in an upsized initial public offering that provided an exit to Otsuka Pharmaceuticals.

SymBiosis and Susquehanna International Group were among a consortium of new and existing backers that supplied $90m in series D financing to Finch Therapeutics.